Sutro Biopharma, Inc. (NASDAQ:STRO) Receives $47.30 Consensus PT from Analysts

by · The Markets Daily

Shares of Sutro Biopharma, Inc. (NASDAQ:STRO – Get Free Report) have been given an average rating of “Buy” by the thirteen research firms that are presently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, ten have given a buy rating and two have assigned a strong buy rating to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $47.30.

A number of equities analysts recently commented on the company. HC Wainwright raised their target price on Sutro Biopharma from $28.00 to $50.00 and gave the company a “buy” rating in a report on Friday, May 15th. Truist Financial initiated coverage on shares of Sutro Biopharma in a research note on Thursday, June 11th. They set a “buy” rating and a $50.00 target price on the stock. Barclays started coverage on shares of Sutro Biopharma in a report on Thursday, May 28th. They set an “overweight” rating and a $56.00 target price on the stock. Mizuho raised shares of Sutro Biopharma to a “strong-buy” rating in a research report on Monday, September 7th. Finally, Citizens Jmp dropped their price target on shares of Sutro Biopharma from $41.00 to $34.00 and set a “market outperform” rating for the company in a research note on Thursday, August 13th.

Read Our Latest Analysis on STRO

Institutional Investors Weigh In On Sutro Biopharma

Several large investors have recently bought and sold shares of the stock. Squarepoint Ops LLC purchased a new stake in shares of Sutro Biopharma during the second quarter worth approximately $1,844,000. California State Teachers Retirement System purchased a new position in Sutro Biopharma in the second quarter worth approximately $242,000. Seven Fleet Capital Management LP acquired a new position in Sutro Biopharma during the 2nd quarter worth approximately $5,283,000. Wellington Management Group LLP acquired a new position in Sutro Biopharma during the 2nd quarter worth approximately $359,000. Finally, Merck & Co. Inc. purchased a new stake in shares of Sutro Biopharma in the 2nd quarter valued at approximately $9,042,053. Hedge funds and other institutional investors own 96.99% of the company’s stock.

Sutro Biopharma Price Performance

Sutro Biopharma stock opened at $16.86 on Wednesday. The firm has a 50 day simple moving average of $23.28 and a 200-day simple moving average of $26.58. The stock has a market cap of $279.54 million, a price-to-earnings ratio of -1.41 and a beta of 1.48. Sutro Biopharma has a 1-year low of $7.15 and a 1-year high of $43.85.

Sutro Biopharma (NASDAQ:STRO – Get Free Report) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($2.33) EPS for the quarter, missing the consensus estimate of ($2.19) by ($0.14). The firm had revenue of $9.84 million for the quarter, compared to analysts’ expectations of $11.96 million. Equities analysts expect that Sutro Biopharma will post -8.41 earnings per share for the current fiscal year.

Sutro Biopharma Company Profile

(Get Free Report)

Sutro Biopharma, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel biologic drug candidates in the fields of oncology and immunology. The company leverages a proprietary cell-free protein synthesis platform, XpressCF™, to design and produce complex, multi-specific proteins that include antibody-drug conjugates, bispecific antibodies, and cytokine fusion proteins. This platform enables rapid generation and optimization of protein therapeutics that may not be feasible with traditional cell-based expression systems.

Founded in 2003 and headquartered in South San Francisco, California, Sutro Biopharma has built a pipeline of immuno-oncology candidates in various stages of preclinical and clinical development.

Read More